Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Supplementary materials br References br Lamont KR Tindal

    2020-08-30


    Supplementary materials
    References
    [2] Lamont KR, Tindall DJ. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011;25:897–907.
    [3] Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Effi-cacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015;67:23–9.
    [4] Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Fer-raldeschi R, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014;50:78–84.
    [7] Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on folli-cle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000;4:275–7.
    [8] Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression fol-lowed by a luteinizing hormone-releasing hormone agonist. BJU Int 2012;110:499–504.
    [10] Hoare D, Skinner TA, Black A, Robert Siemens D. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. Can Urol Assoc J 2015;9:122–7.
    [11] Hurkadli KS, Sheth AR, Garde SV, Doctor VM, Sheth NA. Immuno-cytochemical localisation of follicle stimulating hormone (FSH) in normal, benign and malignant human prostates. Br J Cancer 1990;61:225–9.
    [12] Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petran-geli E, et al. Expression and cellular localization of follicle-stim-ulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175:2072– 7:discussion 7.
    [13] Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, et al. Hormone-refractory prostate cancer λ-Carrageenan express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970–6.
    [14] Heracek J, Urban M, Sachova J, Kuncova J, Eis V, Mandys V, et al. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett 2007;28:45–51.
    [16] Ulloa-Aguirre A, Zarinan T, Pasapera AM, Casas-Gonzalez P, Dias JA. Multiple facets of follicle-stimulating hormone receptor function. Endocrine 2007;32:251–63.
    [17] Simoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and patho-physiology. Endocr Rev 1997;18:739–73.
    [18] Wayne CM, Fan HY, Cheng X, Richards JS. Follicle-stimulating hor-mone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. Mol Endocrinol 2007;21:1940–57.
    [19] Alam H, Weck J, Maizels E, Park Y, Lee EJ, Ashcroft M, et al. Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone. Endocrinology 2009;150:915–28.
    [21] Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, et al. Gankyrin facili-tates follicle-stimulating hormone-driven ovarian cancer cell pro-liferation through the PI3K/AKT/HIF-1alpha/cyclin D1 pathway. Oncogene 2016;35:2506–17.
    [22] Sanchez AM, Flamini MI, Russo E, Casarosa E, Pacini S, Petrini M, et al. LH and FSH promote migration and invasion properties of a breast cancer cell line through regulatory actions on the actin cyto-skeleton. Mol Cell Endocrinol 2016;437:22–34.
    [23] Bose CK. Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncol Res 2008;17:231–8.
    [24] Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hop-wood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577–81.
    [25] Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete andro-gen suppression. Urology 2006;68:834–9.
    [26] Ide H, Terado Y, Sakamaki K, Inoue M, Nakajima A, Lu Y, et al. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer. Prostate Int 2013;1:109–12.
    [27] Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Bio-logic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 2014;21: T87–T103.